Previous winners

2020

Stein-Erik Gullaksen

(University of Bergen, Norway)

For a project which will characterize the interaction of leukemic (CML) and healthy blood cells, and potentially will increase our understanding of the disease biology and therapeutic mechanisms, likely identifying biomarkers of early response to therapy through single cell immune profiling

“I applied for the Incyte Nordic Grant for Hematological Research, because the grant would give me a great opportunity to do the kind of research, which I have always wanted to do but never did, because of a lack of financial support. With the Grant, I have not only received financial support, but it has also given me the possibility to work within an exciting exploratory research field, which may lead to break outs that have never been seen before. I would recommend everyone with the interest of doing research to apply for The Incyte Nordic Grant for Hematological Research. It is a great opportunity for researchers, who aim for new, ground-breaking results, which patients in the future can benefit from.”

2019

Shady Awad

Helsinki

For a project investigating somatic mutations as drivers of treatment resistance and progression of chronic myeloid leukemia

2019

Rebecca Warwinge

Lund

For a project aiming at studying the correlation of CML stem cell heterogeneity to therapy response

2017-2018

Monika Dolinska

Stockholm

For a project aiming at uncovering the features of the CML leukemic cell niche and the role of different niche factors during CML development. Ultimately the project may lead to the identification of novel therapies targeting the leukemic niche for more effective antileukemic treatment.

2017-2018

Linda Arngården

Uppsala

For the development of a new method making it possible to detect and characterize single CML cells, potentially leading to the identification of predictive markers for CML disease remission and relapse after stop of TKI treatment.

2016

Helena Hohtari

Helsinki

For a novel approach to address the challenges of patients with Ph+ acute lymphoblastic leukemia (Ph+ ALL) who are in dire needs of effective therapy. This is to be done through identification of specific molecular/genetic markers predicting response to today’s treatment armamentarium and exploring sensitivity to novel agents. The ultimate goal is to develop curative treatment in Ph+ ALL, including patients not suitable for allogeneic stem cell transplantation.

2015

Jorrit Enserink

Oslo

For a study that has its focus on targeted therapy for Ph+ ALL where therapeutic breakthroughs have remained an unmet need. The study plan is highly interesting aiming at personalized medicine by finding novel molecularly targeted treatments through ex vivo drug profiling using a high throughput drug screen and further by in vivo drug efficacy testing in mouse models.

2015

Satu Mustjoki

Helsinki

For a novel approach to address the challenges of relapsing/progressing CML patients who are in dire needs of effective therapy. This is to be done through identification of driver mutations and involved pathways of pathogenesis and the identification of new targets and modes of action, all aiming at the development of curative combination therapy in CML